[go: up one dir, main page]

WO2008007880A1 - Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses. - Google Patents

Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses. Download PDF

Info

Publication number
WO2008007880A1
WO2008007880A1 PCT/KR2007/003318 KR2007003318W WO2008007880A1 WO 2008007880 A1 WO2008007880 A1 WO 2008007880A1 KR 2007003318 W KR2007003318 W KR 2007003318W WO 2008007880 A1 WO2008007880 A1 WO 2008007880A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
polar solvent
solvent soluble
batsch
prunus persica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2007/003318
Other languages
English (en)
Inventor
Won Yoon Chung
Sun Kyoung Lee
Kwang Kyun Park
Jae Kwan Hwang
Sang Kook Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Publication of WO2008007880A1 publication Critical patent/WO2008007880A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to composition comprising an extract of Prunus persica
  • Bone supports human soft tissues and body weight and protects inner organs such as intestines from outer impacts and shocks by surrounding inner organs. In addition to such supporting functions for muscles and intestines, it has an important function as a reservoir for essential body mineral components such as calcium, phosphorous and magnesium.
  • Inner organs such as intestines
  • it has an important function as a reservoir for essential body mineral components such as calcium, phosphorous and magnesium.
  • Essential body mineral components such as calcium, phosphorous and magnesium.
  • Adult bones with terminated growth are not static, and undergo a dynamic and continuous rebuilding process in which resorption and new bone formation occur. This process is called as bone remodeling (Yamaguchi A. et al., Tanpakushitsu Kakusan Koso., 50(6Suppl). pp. 664-669, 2005).
  • the bone turnover a process in which old bones are removed and replaced with new bones, is pivotal for the repair of micro-damage of bones associated with growth and stress and the maintenance of bone functions (Cohen-Solal M. et al., Therapie., 58f5I pp.391-393, 2003).
  • Bone remodeling has been reported to involve two types of cells. One of them is bone-forming osteoblasts and another is bone-resorbing osteoclasts. Osteoblasts produce RANKL (receptor activator of nuclear factor-kB ligand) and its decoy receptor, OPG (osteoprotegerin). RANKL binds to RANK (receptor activator of nuclear factor- kB) on osteoclast progenitor cells that are then maturated to osteoclasts, finally inducing bone-resorption. However, where OPG binds to RANKL to block the binding between RANKL and RANK, the formation of osteoclasts is inhibited and bone-resorption does not occur at undesirable level (Theill LE.
  • Osteoblasts produced in bone cells are involved in the filling of pores with collagen and covering of pores with precipitates of calcium and phosphorous (hydroxyapatite), thereby forming new bones to rebuild skeleton (Stains JP. et al., birth Defects Res C Embryo Today., 15(Y). pp.72-80, 2005). It takes about 100 days to disrupt old bones and rebuild new bones (Schwarz EM. Et al., Cwrr Opin Orthop., YV, pp. 329-335, 2000). While 100% of calcium content in bone is changed with 1 year in an infant, about 10-30% of the skeleton is rebuilt by the bone remodeling in an adult.
  • Osteoporosis is defined as a disease characterized by low bone mass and deterioration of bone microstructure, causing bone fragility and increased risk of fracture. The disease is developed by unbalanced remodeling exhibiting osteoclastic activities higher than osteoblastic activities (Iqbal MM., South Med J., 93Q). pp.2-18, 2000).
  • osteoporosis bone shows a widened space between structures and a thinner microarchitecture that becomes susceptible to skeletal fractures (Stephan JJ. Et al., Endocr Regul., 37(4 * ). pp.225-238, 2003).
  • Osteoporosis is classified into postmenopausal osteoporosis in which the bone loss (2-3% a year) appears upon initiation of menopause and the risk of spine compression and wrist bone fracture is elevated; senile osteoporosis in which it is developed slowly (0.5-1% a year) in elder men and women aged more than 70 years and induces gradual bone loss of hip and spine bones; and secondary osteoporosis developed by diseases ⁇ e.g., endocrine diseases, gastrointestinal diseases and cancer), drugs (e.g., adrenal cortical hormones, anticancer chemotherapy, thyroid hormones, anticonvulsants, antiplatelets, methotexate, cy- closporine and GnRH), alcohol, smoking or accidents (Rosen CJ., ⁇ Engl J Med., 353(6 * ). pp.595-603, 2005 ; Davidson M., Clinicain Reviews., 12(4 * ). pp.75-82, 2002).
  • the cancer cells entering bones proliferate in bone-surrounding microenvironments and stimulate the activity of osteoclasts or osteoblasts, thereby determining whether the subsequent bone metastasis is osteolytic or osteoblastic (Choong PF., et al., Clin Orthop RelatRes., 415S. pp. S19-S31, 2003).
  • Prunus persica (L.) BATSCH is originated from drainage area of Yellow River in
  • Prunus persica (L.) BATSCH of the present invention is generally classified into white peach and yellow peach.
  • the present inventors investigated the inhibitory effect of the extract or purified extract of white peach and yellow peach on the osteolysis of osteoclast induced by RANKL, and finally found that the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH shows potent inhibitory effect on the formation of osteoclast induced by RANKL as well as on the bone resorption by osteoclast without harmful effect on the cell viability of macrophage cells derived from mouse bone marrow therefore it can be used as the effective and safe therapeutics or health food for treating and preventing bone disease.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the treatment and prevention of bone disease as an active ingredient, together with a pharmaceutically acceptable carrier.
  • the present invention also provides a use of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the preparation of therapeutic agent for treating or preventing bone diseases in a mammal including human in need thereof.
  • the present invention also provides a health food comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an active ingredient for the alleviation and prevention of bone diseases.
  • a method for treating or preventing bone diseases comprising administering to mammal in an effective amount of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
  • the term "crude extract” disclosed herein comprise the extract which can be prepared by extracting plant material with at least one solvent selected from the group consisting of water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, ethyl acetate, ether and chloroform, preferably, the mixture of water and ethanol.
  • polar solvent soluble extract comprise the extract which can be prepared by fractionating above-described crude extract with polar solvent, for example, water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, or the mixture of thereof, preferably, butanol.
  • polar solvent for example, water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, or the mixture of thereof, preferably, butanol.
  • non-polar solvent soluble extract comprise the extract which can be prepared by extracting above-described crude extract with non-polar solvent, for example, ethyl acetate, hexane, chloroform or methylene chloride, preferably, ethyl acetate.
  • bone diseases includes various bone diseases caused by excessive formation of osteoclast induced by RANKL or excessive bone resorption of osteoclast, for example, osteoporosis, rheumatoid arthritis, osteoarthritis, degenerative arthritis, disk, osteomalacia, rickets or polyostotic fibrous dysplasia, preferably, osteoporosis.
  • extract of Prunus persica (L.) BATSCH comprises the extract of the flesh, peel or seed of Prunus persica (L.) BATSCH, preferably, the flesh or the peel of Prunus persica (L.) BATSCH.
  • An inventive extract of Prunus persica (L.) BATSCH can be prepared in detail by following procedures.
  • the flesh of Prunus persica (L.) BATSCH is washed with removing the seed, mixed with 1 to 40-fold, preferably, approximately 1 to 30-fold volume of water, C 1 to C 4 lower alcohols such as ethanol, methanol and the like, or the mixture of thereof, preferably, the mixture of water and ethanol with the mixed ratio ranging from about 1: 0.1 to 1: 10, more preferably, 70 to 100% ethanol or methanol in water; the solution is treated at the temperature ranging from 0 to 120°C, preferably, at the room temperature for the period ranging from 1 to 24 hours, preferably, 3 to 10 hours with extraction method by the extraction with hot water, cold water, reflux extraction or ultra-sonication extracton, preferably, reflux extraction and then dried by vacuum freeze-drying to obtain crude extract of Prunus persica (L.) BATSCH.
  • C 1 to C 4 lower alcohols such as ethanol, methanol and the like, or the mixture of thereof, preferably, the mixture of water and ethanol with the mixed
  • the polar solvent soluble and non-polar solvent soluble extract of present invention can be prepared by following procedure; the crude extract prepared by the above-described step, is suspended in water, and then is mixed with 1 to 100-fold, preferably, 1 to 5-fold volume of non-polar solvent soluble such as hexane, ethyl acetate, chloroform, ether and the like; the non-polar solvent soluble layer is collected to obtain non-polar solvent soluble extract of the present invention and remaining polar solvent soluble layer is collected to obtain polar solvent soluble extract of the present invention which is soluble in water, C to C lower alcohol such as methanol, ethanol, butanol and the like or the mixture thereof; the extract is collected with filtration, concentrated under reduced pressure and dried to obtain an inventive polar solvent soluble extract of Prunus persica (L.) BATSCH.
  • non-polar solvent soluble such as hexane, ethyl acetate, chloroform, ether and the like
  • the inventive composition for treating and preventing bone disease may comprises the above-described extract as 0.1 ⁇ 50 % by weight based on the total weight of the composition.
  • inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the extract of the present invention can be formulated in the form of ointments and creams.
  • compositions containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
  • oral dosage form prowder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule
  • topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
  • injectable preparation solution, suspension, emulsion
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.1 to 1000mg/kg, preferably, 1 to 100 mg/kg by weight/day of the inventive extract of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably, 0.5 to 40% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intra-cerebroventricular injection.
  • a health food or food additives comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH, together with a sitologically acceptable additive for the prevention and alleviation of bone diseases.
  • the health food of the present invention comprises the above-described extract as 0.01 to 80 %, preferably, 1 to 50 % by weight based on the total weight of the composition.
  • the health food of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
  • the health food of the present invention comprises the above-described extract as
  • the food additive of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
  • the present invention provide a composition of the health food beverage for the prevention and improvement of bone diseases adding 0.01 to 80 % the above-described extract by weight, 0.001 to 5 % amino acids by weight, 0.001 to 2 % vitamins by weight, 0.001 to 20 % sugars by weight, 0.001 to 10 % organic acids by weight and proper amount of sweetener and flavors.
  • examples of addable food comprising the above- described extract of the present invention are various food, beverage, gum, vitamin complex, health improving food and the like, and can be used as power, granule, tablet, chewing tablet, capsule or beverage etc.
  • the extract of the present invention will be able to prevent and alleviate bone disease by way of adding to child and infant food, such as modified milk powder, modified milk powder for growth period, modified food for growth period.
  • composition therein can be added to food, additive or beverage, wherein, the amount of above described extract in food or beverage may generally range from about 0.1 to 80w/w %, preferably, 1 to 50 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably, 3 to 10 g on the ratio of IOOD of the health beverage composition.
  • the health beverage composition of present invention contains above described extract as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cy- clodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably, 5 to 12 g in the ratio of 100 D of present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination.
  • the ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition.
  • Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
  • the inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • organic acid such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid
  • phosphate such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate
  • natural anti-oxidants such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.
  • Fig. 1 shows the effect of the ethanol extract of white peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice;
  • Fig. 2 shows the effect of the ethanol extract of yellow peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice;
  • Fig. 3 shows the inhibitory effect of the ethanol extract of flesh part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 5 shows the inhibitory effect of the ethanol extract of flesh part of yellow peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 6 shows the inhibitory effect of the ethanol extract of peel part of yellow peach and the purified fractions thereof on formation of osteoclast;
  • Fig. 7 shows the inhibitory effect of the ethanol extract of peel part of white peach and the butanol soluble fraction thereof on the bone resorption by osteoclast;
  • Fig. 8 shows the inhibitory effect of the ethyl acetate soluble fractions of flesh part and peel part of yellow peach on the bone resorption by osteoclast.
  • the collected residue was evaporated by rotary vacuum evaporator (Heidolph VV2011, Switzerland), dried with lyophilization to obtain various kinds of ethanol extract of peach, i.e., 14.05g of the peel extract of white peach, 13.6Og of the peel extract of white peach, 13.96g of the flesh extract of yellow peach, 13.75g of the peel extract of yellow peach respectively, to use as test samples in following experiments.
  • Example 1 The ethanol extract prepared in Example 1 was suspended in water and the suspension was fractionated with ethyl acetate, butanol and distilled water to afford ethyl acetate-soluble fraction, butanol-soluble fraction and water-soluble fraction of the present invention. The fractions were filtered and the filtrates were evaporated to obtain ethyl acetate-soluble fraction as a non-polar solvent soluble extract and the butanol-soluble fraction and water-soluble fraction as polar solvent soluble extract of the present invention.
  • Mouse bone marrow macrophage cell (1 x 10 4 cells) was added to each well of 96 well plates and cultured in ⁇ -MEM containing 1% of antibiotic-antimycotic solution, 10% of FBS (fetal bovine serum), 30 ng/ml of M-CSF (macrophage-colony stimulating factor), and the ethanol extract of flesh part of white peach, the ethanol extract of peel part of white peach, the ethyl acetate soluble fractions thereof, the butanol soluble fractions thereof, or the water soluble fractions thereof as test samples.
  • FBS fetal bovine serum
  • M-CSF macrophage-colony stimulating factor
  • test samples prepared in Example 1 and 2 were dissolved in DMSO (dimethyl sulfoxide) and water, and the solutions were diluted with 10% FBS- ⁇ -MEM to the concentration of 0, 1, 10, 100 D/ml.
  • the mouse bone marrow macrophage cells were cultured by changing with fresh new medium every 2 days, and incubated for 5 days at 37 °C in 5% CO incubator.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
  • the cell viability was calculated by the percentage ratio of absorbance of test sample groups comprising the extract ofPrunus persica (L.) BATSCH or the fraction thereof to the absorbance of control treated with only medium.
  • Mouse bone marrow macrophage cells were added to 96 well plates in a concentration of IxIO 4 cells per each well and incubated in 10% FBS- ⁇ -MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), and 100 D/ml of the ethanol extract of flesh part or peel part of white peach or 100 D/ml of ethyl acetate-soluble fraction, butanol- soluble fraction, or water-soluble fraction of flesh part or peel part of white peach.
  • FBS- ⁇ -MEM containing RANKL 100 ng/ml
  • M-CSF 30 ng/ml
  • 100 D/ml of the ethanol extract of flesh part or peel part of white peach 100 D/ml of ethyl acetate-soluble fraction, butanol- soluble fraction, or water-soluble fraction of flesh part or peel part of white peach.
  • mice The mouse bone marrow macrophage cells separated from the hind legs of 4- weeks aged mice were added to 24 well plates coated with calcium phosphate with a concentration of 5xlO 4 cells per each well. 10% FBS- ⁇ -MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), the ethanol extract of peel part of white peach (75, 100 D/ml) and butanol-soluble fraction of peel part of white peach (75, 100 D/ml) was added to each well.
  • FBS- ⁇ -MEM containing RANKL 100 ng/ml
  • M-CSF 30 ng/ml
  • the ethanol extract of peel part of white peach 75, 100 D/ml
  • butanol-soluble fraction of peel part of white peach 75, 100 D/ml
  • the ethyl acetate-soluble fraction of flesh part of yellow peach (10, 50 D/ml) and the ethyl acetate-soluble fraction of peel part of yellow peach (10, 50 D/ml) were added thereto to incubate for 15 days with changing fresh medium every 2 days. After the incubation, the medium was removed and sodium hypochlorite solution was added thereto. 5 minutes after the reaction, the sodium hypochlorite solution was removed and plate was washed with distilled water twice. The resorption pit formed by osteoclasts was observed by optical microscope.
  • Powder preparation was prepared by mixing above components and filling sealed package.
  • Tablet preparation was prepared by mixing above components and entabletting.
  • Capsule preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method. [140]
  • Injection preparation was prepared by dissolving the components in 2D ample and sterilizing by conventional injection preparation method. [147]
  • Vitamin mixture optimum amount
  • Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85 0 C for 1 hour, filtered and then filling all the components in 2000D ample and sterilizing by conventional health beverage preparation method.
  • the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention porte sur un extrait cru de Prunus persica (L.) BATSCH soluble dans un solvant polaire ou non polaire, inhibant la formation d'ostéoclastes dans les macrophages de moelle osseuse de souris traités par du RANKL et la résorption osseuse par les ostéoclastes sans avoir d'effets négatifs sur la viabilité des cellules macrophages de moelle osseuse de souris. On peut donc l'utiliser en tant que remède ou aliment de santé pour traiter et prévenir les maladies osseuses.
PCT/KR2007/003318 2006-07-14 2007-07-09 Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses. Ceased WO2008007880A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0066236 2006-07-14
KR1020060066236A KR100823354B1 (ko) 2006-07-14 2006-07-14 복숭아 추출물을 함유하는 골 질환의 예방 및 치료용조성물

Publications (1)

Publication Number Publication Date
WO2008007880A1 true WO2008007880A1 (fr) 2008-01-17

Family

ID=38923409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/003318 Ceased WO2008007880A1 (fr) 2006-07-14 2007-07-09 Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses.

Country Status (2)

Country Link
KR (1) KR100823354B1 (fr)
WO (1) WO2008007880A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704765B1 (ko) 2016-05-06 2017-02-08 주식회사 금시조 갑상선 질환 개선용 복숭아 나무 추출 환 및 액상차
WO2018048140A1 (fr) * 2016-09-07 2018-03-15 연세대학교 산학협력단 Composition pharmaceutique destinée à la prévention ou au traitement des maladies osseuses
KR102186886B1 (ko) * 2018-07-11 2020-12-04 한국 한의학 연구원 프루누스 자마사쿠라 추출물을 유효성분으로 함유하는 골다공증의 예방, 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010067023A (ko) * 2000-12-13 2001-07-12 류희영 골다공증, 관절통, 관절염 치료제 및 그 제조 방법
JP2002338485A (ja) * 2001-05-22 2002-11-27 Hideko Iizuka 病気の治療の為のジュースの作り方
KR100518686B1 (ko) * 2001-06-26 2005-11-08 한국 한의학 연구원 성장호르몬 분비촉진용 생약추출물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010067023A (ko) * 2000-12-13 2001-07-12 류희영 골다공증, 관절통, 관절염 치료제 및 그 제조 방법
JP2002338485A (ja) * 2001-05-22 2002-11-27 Hideko Iizuka 病気の治療の為のジュースの作り方
KR100518686B1 (ko) * 2001-06-26 2005-11-08 한국 한의학 연구원 성장호르몬 분비촉진용 생약추출물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARJMANDI B.H. ET AL.: "Dried plums improve indices of bone formation in postmenopausal women", J. WOMENS HEALTH GEND. BASED MED., vol. 11, no. 1, 2002, pages 61 - 68, XP009056026, DOI: doi:10.1089/152460902753473471 *
DEYHIM F. ET AL.: "Dried plum reverses bone loss in an osteopenic rat model of osteoporosis", MENOPAUSE, vol. 12, no. 6, 2005, pages 755 - 762 *

Also Published As

Publication number Publication date
KR20080006907A (ko) 2008-01-17
KR100823354B1 (ko) 2008-04-17

Similar Documents

Publication Publication Date Title
US10980842B2 (en) Composition for promotng bone formation with fermented oysters and seaweed
KR101686490B1 (ko) 흑미 추출물을 유효성분으로 하는 골대사 질환 예방 또는 치료용 조성물
KR102081984B1 (ko) 새싹밀 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
JP6026639B2 (ja) フジバカマ属の抽出物を含有する骨代謝疾患の予防及び治療用組成物及びその製造方法
KR102286429B1 (ko) 연잎 유래 다당 분획물을 함유하는 골 관련 질환의 개선, 예방 또는 치료용 조성물
KR102372440B1 (ko) 비쑥 추출물을 유효성분으로 포함하는 골대사성 질환으로 유발된 골소실 예방 또는 치료용 약제학적 조성물
KR101039053B1 (ko) 물레나물 추출물을 유효성분으로 하는 골질환 예방 및 치료용 조성물
KR20180135567A (ko) 새싹보리 추출물을 포함하는 갱년기 장애의 예방 또는 치료용 조성물
WO2008007880A1 (fr) Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses.
KR101249930B1 (ko) 마가목 및 현지초 추출물을 포함하는 파골세포 분화 억제용 또는 연골세포 분화 촉진용 조성물(ｓｇ-ⅱ)
KR20160149049A (ko) 흑미 호분층의 추출물을 유효성분으로 함유하는 골다공증 예방 및 치료용 약학적 조성물
KR20240134840A (ko) 안토시아닌을 유효성분으로 포함하는 조골세포 분화 촉진용 조성물
KR101444760B1 (ko) 우슬과 희렴의 혼합 추출물을 함유하는 골대사 질환 예방 및 골 기능 개선을 위한 조성물
KR101972657B1 (ko) 자화전호 추출물 또는 이로부터 분리된 화합물을 포함하는 골다공증 치료 또는 예방용 조성물
KR101052501B1 (ko) 생약재 추출물을 유효성분으로 함유하는 골 질환의 예방 및 치료용 조성물
KR20170069413A (ko) 발아 흑미 추출물을 유효성분으로 하는 비만 또는 골대사 질환 예방 또는 치료용 조성물
KR102448913B1 (ko) 미선나무 추출물을 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
KR101753057B1 (ko) 인지기능장애 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
KR101120499B1 (ko) 골 질환의 예방 및 치료용 조성물
KR102151643B1 (ko) 표고버섯 추출물을 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
KR101885667B1 (ko) 조골세포 분화를 촉진하며 지방세포 분화를 저해하는 벼 추출물 및 그 용도
KR102160627B1 (ko) 헛개나무 가지 추출물을 함유하는 골 질환의 예방 또는 치료용 약학적 조성물
KR102448274B1 (ko) 보골지 추출물의 조다당 분획물을 유효성분으로 함유하는 골질환의 예방, 개선 또는 치료용 조성물
KR20150105561A (ko) 헛개나무 추출물을 함유하는 골 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07768659

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07768659

Country of ref document: EP

Kind code of ref document: A1